Blog

Epilepsy affects 68 million people worldwide [1]. In high-income countries, poorly controlled epilepsy is generally a feature of complicated cases of antiepileptic drug (AED) resistance, for which treatment options include surgery, non-pharmacological treatments, and molecular “precision therapies” [2,3]. However, the state of poorly controlled epilepsy differs dramatically in low- and middle-income countries (LMICs), where the global burden of epilepsy is concentrated and 80% of people with epilepsy (PWE) live [4,5].